St. Jude Medical Broadens Treatment Options for Patients Suffering Movement Disorders with the European Launch of New Deep Brain Stimulation System and Directional Lead
St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the European launch of the St. Jude Medical Infinity™ Deep Brain Stimulation (DBS) System and directional DBS lead. The system, which received CE Mark approval late in 2015, will support the treatment of patients with the three most common movement disorders in the world: Parkinson’s disease, tremor and dystonia, a disorder which causes involuntary muscle contractions.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160616005419/en/
Movement disorders are neurologic conditions caused by a communication breakdown throughout the central nervous system that can result in a debilitating loss of muscle control, involuntary movement and reduced coordination. There are currently no proven cures for movement disorders, which means treatment options focus on alleviating symptoms to improve quality of life. St. Jude Medical designed the Infinity system to improve the experience of patients who rely on DBS therapy to manage their symptoms. The company also developed the St. Jude Medical directional lead to help physicians more accurately tailor DBS therapy to their patient’s specific needs while reducing side effects.
The first physician to implant the new Infinity system and the St. Jude Medical directional lead was Prof. Jan Vesper, a professor of functional neurosurgery and stereotaxy at the University Hospital in Düsseldorf, Germany, and president of the German Neuromodulation Society.
“The Infinity system is the first DBS system I’ve encountered that adjusts to the patient’s individual needs, rather than forcing the patient to adjust to the system,” said Prof. Vesper. “Offering my patients a DBS system with exceptional ease of use and smooth manageability is an exciting step in the treatment of debilitating movement disorders.”
A DBS system, like the St. Jude Medical Infinity DBS system, delivers mild electrical pulses to specific targets in the brain to stimulate the structures involved in motor control. With the launch of the Infinity system, St. Jude Medical aims to empower physicians to more accurately deliver stimulation with a DBS system. The new St. Jude Medical directional lead can deliver stimulation more precisely through eight independent electrodes that allow physicians to specifically direct current to targeted structures and areas of the brain. This advance will allow physicians to tailor the therapy to a patient’s specific needs while avoiding unnecessary stimulation to areas that may create side effects.
The Infinity system also offers new, distinct patient advantages. For patient comfort, the system is available in two different sizes, offers a maintenance-free and long-lasting recharge-free system, and uses Bluetooth® wireless technology and Apple™ digital devices for its patient controller and physician programmers. In addition, the St. Jude Medical Infinity system is also upgradeable, which provides patients the potential to access new therapy advances as they’re approved without the need for repeat surgery.
“The Infinity DBS system and directional lead design was designed to meet the needs of physicians who confirmed that they needed a system that prioritized improved stimulation targeting, device longevity and improved patient ease of use,” said Dr. Allen Burton, medical director of neuromodulation and vice president of medical affairs at St. Jude Medical. “The Infinity DBS system is our answer for these previously unmet needs, demonstrating St. Jude Medical’s commitment to patient-centric solutions that help alleviate the debilitating effects of movement disorders.”
Note: Apple, is a trademark of Apple, Inc. Bluetooth is a trademark of Bluetooth SIG, Inc.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer and is dedicated to transforming the treatment of some of the world's most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical employs approximately 18,000 people worldwide and has five major areas of focus that include heart failure, atrial fibrillation, neuromodulation, traditional cardiac rhythm management and cardiovascular. For more information, please visit sjm.com or follow us on Twitter @SJM_Media .
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal quarter ended April 2, 2016. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Information om Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Følg pressemeddelelser fra Business Wire
Skrive dig op her og du vil løbende modtage pressemeddelelser på mail. Indtast din mail, klik på abonner og følg instruktionerne i den udsendte mail.
Flere pressemeddelelser fra Business Wire
TAN-DELTA23.11.2017 14:40 | pressemeddelelse
Tan Delta: New Oil Condition Monitoring Kit for Gas Engine Operators Reduces Daily Operating Costs, Improves Equipment Efficiency and Extends Equipment Life.
INSTITUT-CURIE23.11.2017 14:02 | pressemeddelelse
Making Institut Curie a Reference for Technology Transfer in Oncology
WEALTH-DYNAMIX23.11.2017 09:02 | pressemeddelelse
Wealth Dynamix (WDX) Ranks No.18 in the 2017 Tech Track 100 by the Sunday Times and 19th Fastest Growing Technology Company in the UK in the 2017 Deloitte Technology Fast 50
MOBIDIAG-LTD23.11.2017 08:02 | pressemeddelelse
Mobidiag Signs Agreement with Interlux for the Distribution of Amplidiag® Diagnostic Tests and Instruments in Estonia
OCP-S.A.22.11.2017 18:01 | pressemeddelelse
OCP Announces Date of 2017 Third Quarter and Nine Month Results
TATA-MOTORS22.11.2017 15:48 | pressemeddelelse
Tata Motors Charts Out 'Connecting Aspirations' As Its New Corporate Brand Identity in Global Markets
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter, og finde vores kontaktoplysninger.Besøg vores nyhedsrum